|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heiden MG Vander, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kroemer G and Pouyssegur J: Tumor cell
metabolism: Cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heiden MG Vander: Targeting cancer
metabolism: A therapeutic window opens. Nat Rev Drug Discov.
10:671–684. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singleterry J, Sreedhar A and Zhao Y:
Components of cancer metabolism and therapeutic interventions.
Mitochondrion. 17:50–55. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Swietach P, Vaughan-Jones RD and Harris
AL: Regulation of tumor pH and the role of carbonic anhydrase 9.
Cancer Metastasis Rev. 26:299–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tao T, Li G, Dong Q, Liu D, Liu C, Han D,
Huang Y, Chen S, Xu B and Chen M: Loss of SNAIL inhibits cellular
growth and metabolism through the miR-128-mediated
RPS6KB1/HIF-1α/PKM2 signaling pathway in prostate cancer cells.
Tumour Biol. 35:8543–8550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Warburg O: On respiratory impairment in
cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
|
|
10
|
Yeung SJ, Pan J and Lee MH: Roles of p53,
MYC and HIF-1 in regulating glycolysis - the seventh hallmark of
cancer. Cell Mol Life Sci. 65:3981–3999. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu PP and Sabatini DM: Cancer cell
metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mathupala SP, Ko YH and Pedersen PL:
Hexokinase-2 bound to mitochondria: Cancer's stygian link to the
‘Warburg Effect’ and a pivotal target for effective therapy. Semin
Cancer Biol. 19:17–24. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pedersen PL, Mathupala S, Rempel A,
Geschwind JF and Ko YH: Mitochondrial bound type II hexokinase: A
key player in the growth and survival of many cancers and an ideal
prospect for therapeutic intervention. Biochim Biophys Acta.
1555:14–20. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wolf A, Agnihotri S, Micallef J, Mukherjee
J, Sabha N, Cairns R, Hawkins C and Guha A: Hexokinase 2 is a key
mediator of aerobic glycolysis and promotes tumor growth in human
glioblastoma multiforme. J Exp Med. 208:313–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grasso CS, Wu YM, Robinson DR, Cao X,
Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC,
et al: The mutational landscape of lethal castration-resistant
prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang C, Zhang J, Hao J, Shi Z, Wang Y,
Han L, Yu S, You Y, Jiang T, Wang J, et al: High level of
miR-221/222 confers increased cell invasion and poor prognosis in
glioma. J Transl Med. 10:1192012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang XF, Shi ZM, Wang XR, Cao L, Wang YY,
Zhang JX, Yin Y, Luo H, Kang CS, Liu N, et al: MiR-181d acts as a
tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer
Res Clin Oncol. 138:573–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Malvezzi M, Carioli G, Bertuccio P, Rosso
T, Boffetta P, Levi F, La Vecchia C and Negri E: European cancer
mortality predictions for the year 2016 with focus on leukaemias.
Ann Oncol. 27:725–731. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tao T, Liu D, Liu C, Xu B, Chen S, Yin Y,
Ang L, Huang Y, Zhang X and Chen M: Autoregulatory feedback loop of
EZH2/miR-200c/E2F3 as a driving force for prostate cancer
development. Biochim Biophys Acta. 1839:858–865. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang YA and Yu J: EZH2, an epigenetic
driver of prostate cancer. Protein Cell. 4:331–341. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim J and Yu J: Interrogating genomic and
epigenomic data to understand prostate cancer. Biochim Biophys
Acta. 1825:186–196. 2012.PubMed/NCBI
|
|
24
|
Varambally S, Cao Q, Mani RS, Shankar S,
Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, et al:
Genomic loss of microRNA-101 leads to overexpression of histone
methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sauvageau M and Sauvageau G: Polycomb
group proteins: Multi-faceted regulators of somatic stem cells and
cancer. Cell Stem Cell. 7:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Berezovska OP, Glinskii AB, Yang Z, Li XM,
Hoffman RM and Glinsky GV: Essential role for activation of the
Polycomb group (PcG) protein chromatin silencing pathway in
metastatic prostate cancer. Cell Cycle. 5:1886–1901. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hoffmann MJ, Engers R, Florl AR, Otte AP,
Muller M and Schulz WA: Expression changes in EZH2, but not in
BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation
changes in prostate cancer. Cancer Biol Ther. 6:1403–1412. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani
RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al: Repression
of E-cadherin by the polycomb group protein EZH2 in cancer.
Oncogene. 27:7274–7284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu J, Cao Q, Mehra R, Laxman B, Yu J,
Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, et al:
Integrative genomics analysis reveals silencing of beta-adrenergic
signaling by polycomb in prostate cancer. Cancer Cell. 12:419–431.
2007. View Article : Google Scholar : PubMed/NCBI
|
